Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Antibe Therapeutics Inc. (T:ATE)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ATE within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Aug 15, 2022 07:00 ET
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal quarter ended June 30, 2022.
Read full article
Jun 30, 2022 07:00 ET
Antibe Therapeutics Reports 2022 Year-End Results and Business Highlights
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial and operating results for the fiscal year ended March 31, 2022.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
-0.03
--
--
Price to Sales - TTM
--
4.68
4.28
Price to Book - most recent quarter
0.65
2.48
1.92
Price to Cash Flow per share - TTM
--
3.44
9.27
Price to Free Cash Flow per share - TTM
--
5.49
18.12
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Aug 15, 202227,436-25,067
Jul 31, 202252,503-39,047
Jul 15, 202291,5508,398
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation, and regenerative medicine. The Company's products pipeline includes Otenaproxesul, ATB-352, and ATB-340. Otenaproxesul is a novel anti-inflammatory drug that releases hydrogen sulfide and combines hydrogen sulfide with naproxen, non-steroidal, anti-inflammatory drug. ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen. ATB-340 is a gastrointestinal-safe version of low-dose aspirin for cardiovascular and cancer protection. The Company, through its wholly owned subsidiary, Citagenix Inc. (Citagenix) is a seller of tissue regenerative products servicing the orthopaedic and dental marketplaces. Citagenix's portfolio consists of branded biologics and medical devices that promote bone regeneration.

See business summary

 

Twitter

Search (past week) for $ATE.CA

  • No tweets found